Recursion Pharmaceuticals, Inc. (RXRX)

9,50 +0,90 (+10,47%) A partir del 03:50PM EDT. Mercado abierto.

Recursion Pharmaceuticals, Inc.

41 South Rio Grande Street
Salt Lake City, UT 84101
United States
385 269 0203
https://www.recursion.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 500

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Christopher C. Gibson Ph.D.	Co-Founder, CEO & Director	806,72k	2,18M	1983
Ms. Tina Marriott Larson	COO & President	702,24k	397,61k	1975
Dr. Blake C. Borgeson Ph.D.	Co-Founder & Director	40k	N/A	1982
Dr. Michael Secora Ph.D.	Chief Financial Officer	629,78k	3,62M	1983
Dr. David J. Mauro M.D., Ph.D.	Chief Medical Officer	674,74k	N/A	1965
Kevin Leggat	Vice President of Finance & Accounting	N/A	N/A	N/A
Mr. Benjamin Mabey M.S.	Chief Technology Officer	N/A	N/A	1983
Mr. Jared Allenbach	Senior Director of Investor Relations	N/A	N/A	N/A
Mr. Nathan Hatfield	Chief Legal Officer & General Counsel	N/A	N/A	N/A
Mr. Ryan Kelly	Chief Communications Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Gobierno corporativo

El ISS Governance QualityScore de Recursion Pharmaceuticals, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 1; Tablero: 6; Derechos de los accionistas: 10; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.